The clinical outcomes of the MADEOS trial (NCT03297515) is discussed in this touchOPHTHALMOLOGY interview with Dr Katerina Prokopiou (University of Nicosia Medical School, Engomi, Cyprus). Currently, there is no effective treatment available that stops progression or improves vision in patients with dry age-related macular degeneration or Stargardt disease, the MADEOS trial assesses the therapeutic potential of omega-3 fatty acids supplementation in these conditions.
The presentation entitled ‘A prospective, multicentre, randomised, double-blind study designed to assess the potential effects of omega-3 fatty acids supplementation in dry age-related macular degeneration or Stargardt disease’ was presented at the The Association for Research in Vision and Ophthalmology, May 01-04, 2022
Questions:
- What were the aims and design of your study?
- What were the study endpoints and how well were they achieved?
- What were the conclusions of the investigations and what further research is planned?
Disclosures: Katerina Prokopiou has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual ARVO 2022.
